Indian Gum Arabic Tree (Vachellia nilotica syn. Acacia nilotica): A Comprehensive Reference
1. Identity and Botanical Classification
1.1 Nomenclature and Taxonomy
Vachellia nilotica, more commonly known as Acacia nilotica, and by the vernacular names of gum arabic tree, babul, thorn mimosa, Egyptian acacia, or thorny acacia, is a flowering tree in the family Fabaceae. It is native to Africa, the Middle East, and the Indian subcontinent. This species of tree is the type species of the Linnaean genus Acacia, which derives its name from the Greek ἀκακία (akakía), the name given by early Greek botanist-physician Pedanius Dioscorides (c. AD 40–90) to this tree as a medicinal, in his book Materia Medica. The genus Acacia was long known not to be taxonomically monophyletic, and despite being the type species of that genus, A. nilotica has since been moved to the genus Vachellia, with the genus name Acacia being reserved for Australian species; the principle of priority, which would normally prevent such a taxonomic change, was waived with a majority vote by the International Botanical Congress in 2005.
The plant has accumulated a large number of botanical synonyms reflecting its wide geographical distribution and long period of formal study. Its botanical name has been rendered as Acacia arabica Willd., and it belongs to the subfamily Mimosoideae of the family Fabaceae (formerly Leguminosae). In English, it is known as Babul, Black Babul, and Indian Gum Arabic Tree. Other English names include Tomentose Babool, Black Babul, Egyptian mimosa, Egyptian thorn, Prickly Acacia, Nile acacia, Scented thorn, and Scented-pod acacia; and in Arabic it is known by names such as Ummughilan, Usarequrz, and kaarad. It is also commonly known as babul, kikar, or Indian gum Arabic tree.
In the scientific literature, Acacia nilotica (L.) Willd, a member of the Fabaceae family, is commonly referred to as the Indian gum arabic tree, kikar, or babul, which has gained recognition as a versatile and valuable tree species.
1.2 Morphological Description
The Indian gum arabic tree is a thorny tree 8–10 m high, with a grey trunk and branches that hang straight downwards. Tender branches are used for brushing teeth. The tree bears 10 to 20 pairs of leaflets, yellow flowers, and legumes 7 to 10 cm long containing 8–10 white seeds. Flowers are in globulous heads 1.2–1.5 cm in diameter of a bright golden-yellow color, set up either axillary or in whorls on peduncles 2–3 cm long located at the end of branches. Pods are strongly constricted, hairy, white-grey, thick, and softly tomentose. A brownish-white gum exudes from the trunk and is available in the market.
1.3 Common Forms and Preparations
All major parts of the tree are used medicinally. Acacia nilotica is available in the form of bark, pods, leaves, seeds, and gum. These parts can be prepared as decoctions, powders, pastes, exudates, or smoke. It can be infused into oils or tea or incorporated into paste, poultice, and biscuits, used as an emollient, antidiarrheal, astringent, and as an antidote for bite poisons. In commercial and dietary supplement contexts, the plant is most commonly encountered as a powdered bark or pod extract, a standardized gum exudate, and less commonly as a twig preparation used for oral hygiene.
The exudate gum of this tree is known as gum arabic and has been collected since pharaonic times for the manufacture of medicines, dyes, and paints. In the present commercial market, gum arabic is defined as the dried exudate from the trunks and branches of Senegalia (Acacia) senegal or Vachellia (Acacia) seyal. The gum of A. nilotica is also referred to in India as Amaravati gum.
2. Traditional and Historical Use
2.1 Ancient Egypt
Timber had a religious importance in the civilizations of the ancient Near East and was a major source of materials utilized in buildings in addition to its uses in traditional medicine. In ancient Egypt, the timbers and trees were presented on paintings of the tombs and in archaeological remnants. Historical review focuses on the significance of the Acacia nilotica tree in the religious and funerary context as well as its distribution, history, uses, and benefits in the ancient Egyptian diet, industry, and medical treatments from ancient Egyptian ages up to the present day. The exudate gum of this tree has been collected since pharaonic times for the manufacture of medicines, dyes, and paints. Herodotus, who was travelling in Egypt during the fifth century B.C., refers to the use of acacia wood not only for boat building but also for masts. Another Greek writer, the botanist Theophrastus, states that acacia was used for roofing and for the ribs of ships.
2.2 Ayurveda and Indian Traditional Medicine
V. nilotica has been widely used as traditional medicine in Unani and Ayurveda medicine systems for hundreds of years with no reports of toxicity or adverse effects. The bark of Babul has been used in Ayurveda, Unani, and folk medicine for oral health, wound healing, diarrhea, and skin diseases. In Ayurvedic classical texts, the plant is known by names such as Babbuula, Babbuuri, Baavari, Aabhaa, Shuulikaa, Shitaka, Kinkiraata, Yugmakantaka, Sukshmapatra, and Pitapushpaka. In this system it is considered useful in diarrhoea, dysentery, piles, helminthiasis, bleeding disorders, cough, and urinary disorders. The gum is used for dysuria and loss of libido.
A. nilotica has medicinal properties as per Unani, traditional Chinese medicine (TCM), and Ayurvedic texts. In the Unani tradition, it is known as babool. According to the Unani school of medicine, babool (Acacia arabica) provides therapeutic advantages for a number of human body systems. The bark, root, gum, leaves, pod, and seeds of the plant are among the parts that have medicinal applications, and Acacia arabica, popularly known as babool, has a wide range of ethnobotanical and Unani traditional uses.
2.3 Africa, the Middle East, and Other Traditions
For thousands of years, Vachellia nilotica has been widely used as an herbal medicine to treat some diseases and symptoms, including respiratory, gastrointestinal, and urogenital ailments. East African tribes living on the savanna use this plant medicinally to treat sore throat, cough, and chest pains. The Maasai people eat both the inner bark (phloem) and the fruit pulp boiled in water. In Kano of Nigeria, acacia pods have traditionally been used to dye leather a reddish tinge.
In Western Africa, various plant parts have been used for treatment of tumor/cancer of the ear, eye, and testicles, tuberculosis (roots), smallpox (wood), ulcers (leaves), and indurations of the liver and spleen (bark and gum). Nubians in South Egypt believe that diabetic patients can be treated with powdered pods of A. nilotica, as they are effective in regulating blood glucose levels, and this use has been documented in folk medicine to treat diabetes mellitus. Decoction of pod extract is used for postpartum wound healing in Katsina state of Nigeria.
In the context of oral health, the plant has been used in dantadhavan (tooth cleansing) for treating bleeding gums, bad breath, and strengthening teeth, and bark decoction is administered to manage chronic diarrhea and dysentery due to its astringent and antimicrobial effects. The tender twig of this plant is used as a toothbrush in South-East Africa and the Indian subcontinent.
3. Key Constituents and Active Compounds
3.1 Overview of Phytochemistry
Over 150 chemical components have been identified from V. nilotica that could be associated with its potential actions. The principal phytochemicals identified in this plant are tannins, flavonoids, alkaloids, saponins, glycosides, terpenoids, steroids, volatile oils, and carbohydrates. The phytochemical profile varies meaningfully by plant part and extraction solvent, but certain classes of compounds are consistently identified across tissues.
Phytochemical studies have revealed that the major constituents of Acacia nilotica include tannins (especially gallotannins and catechins), flavonoids (such as quercetin, kaempferol, and rutin), saponins, alkaloids, glycosides, essential oils, and polysaccharides (gum exudates). The plant also contains ascorbic acid, carotene, protein, fibre, arabin, calcium, magnesium, and selenium.
3.2 Major Identified Compounds
Quercetin, rutin, kaempferol, naringenin, catechin, epicatechin, gallic acid, ellagic acid, lupeol, and niloticane are its main active constituents. More specifically in the fruit/flower fractions, HPLC analysis has detected significant phenolic and flavonoid content: various compounds including ferulic acid (5451.04 µg/mL), chlorogenic acid (4572.26 µg/mL), quercetin (3733.37 µg/mL), rutin (2393.13 µg/mL), gallic acid (2116.77 µg/mL), cinnamic acid (69.72 µg/mL), hesperetin (121.39 µg/mL), and methyl gallate (140.45 µg/mL) have been detected.
Phenolic compounds (ellagic acid, gallic acid, and ethyl brevifolin-carboxylate) are among the most abundant constituents, followed by triterpenes (oleanolic, ursolic, maslinic, and asiatic acids), the flavonoid punicaflavone, anthocyanins (pelargonidin 3,5-diglucoside and pelargonidin 3-glucoside), sterols, daucosterol, and tannins.
The gum exudate has its own distinct chemistry. Gum arabic is a complex mixture of glycoproteins and polysaccharides, predominantly polymers of arabinose and galactose. More precisely, gum arabic consists mainly of high molecular weight polysaccharides and their magnesium, calcium, and potassium salts which on hydrolysis yield galactose, arabinose, glucuronic acid, and rhamnose.
Phytochemical analysis of ethanol and petroleum ether extracts from the stem bark of Acacia nilotica revealed the presence of terpenoids, tannins, alkaloids, saponins, and glycosides. Meanwhile, the leaves have been found rich in phenols, flavonoids, triterpenoids, and tannin content. Phytochemical analysis of the aqueous, ethyl acetate, and N-butanol fractionated portions of the pod extracts of A. nilotica revealed the presence of tannins, saponins, flavonoids, and carbohydrates.
Apart from high phenolic and flavonoid content, tocopherol, catechol, and β-sitosterol have been identified in leaf extract, demonstrating substantial binding affinity with Nrf2 protein, reflecting possible crosstalk with intracellular antioxidant defense pathways. Two new antiprotozoal diterpenes have also been isolated from the root bark of Acacia nilotica.
3.3 Mechanisms of Action
The active constituents have a variety of potential activity, such as anti-inflammatory, antioxidant, antipyretic, analgesic, antibacterial, antifungal, antiviral, glucose-lowering, lipid-lowering, anti-proliferative, antiulcer, antidiuretic, and antidiarrheal activities. These potential activities are ascribed to phytochemical constituents that actively interact with essential targets, exerting biological effects.
Tannins: Gallnuts have high hydrolysable tannin (gallotannin) content (50–70%), which causes a strong astringent and anti-secretory effect. Tannins are also known to promote wound healing by promoting wound contraction, scavenging of free radicals, fibroblast formation, and angiogenesis.
Flavonoids and Antidiabetic Mechanism: Compounds like catechin, epicatechin, quercetin, kaempferol, and luteolin present in V. nilotica have been shown to exhibit insulin-sensitizing effects. These flavonoids can improve glucose uptake in peripheral tissues. Quercetin and kaempferol are two flavonoids that increase insulin sensitivity, making the plant a potential tool for managing diabetes. Gallic acid and ellagic acid are two tannins that fight oxidative stress and shield cells from harm.
Antioxidant Pathway: Natural antioxidants like flavonoids, phenolics, tannins, and terpenoids present in Vachellia nilotica can reduce the access of oxidants and other deleterious molecules due to their ability to scavenge oxygen-nitrogen-derived free radicals by donating a hydrogen atom or an electron, chelating metal catalysts, activating antioxidant enzymes.
Analgesic/Anti-inflammatory Pathway: The antinociceptive effects of extracts may be due to their content of flavonoids, tannins, alkaloids, and saponins. In a study by Safari et al. (2016), antinociceptive effect was reported from the leaf extract of V. nilotica reducing the formalin-induced paw licking time in both acute and chronic pain phases, with the highest analgesic effect at a 50 mg/kg dose level. These findings suggest both direct analgesic effects on nociceptor blockage and an inhibition of the synthesis and/or release of inflammatory pain mediators such as prostaglandins.
4. Scientific Evidence by Area of Use
4.1 Antimicrobial Activity
Antimicrobial properties constitute one of the best-researched areas for this plant, though the bulk of evidence remains at the in vitro level. A. nilotica showed antibacterial activity against most gram-positive and gram-negative bacteria, suggesting a broad-spectrum antibacterial property. Leaf extracts of A. nilotica showed antimicrobial activity against nine microorganisms.
In relation to oral pathogens specifically, plant extracts showed significant antibacterial activity with maximum activity (14 ± 0.9 mm zone of inhibition by Acacia nilotica) in 100% solution, and it can be concluded that methanolic extract of traditional therapeutic plants proved to be a promising source of antimicrobial agents against antibiotic resistant bacteria. Acacia nilotica was observed to be a competent antibacterial tool against pathogenic bacterial strains.
Against fungal pathogens, the aqueous extract of V. nilotica showed antifungal activity against standard strains and 46 clinical isolates of Candida albicans at concentrations of 5 mg/dL and 10 mg/dL.
An in vitro study targeting Helicobacter pylori found that A. nilotica's anti-H. pylori activity was demonstrated, with strong anti-H. pylori activity at a 31 mm inhibition zone, compared to the positive control at 21.67 mm.
Antiviral activity has also been examined in vitro. Crude extract of Acacia arabica leaves showed significant antiviral effect and also prophylactic activity against viral infection in an in vitro study.
Evidence assessment: Antimicrobial evidence is predominantly in vitro. While multiple studies consistently demonstrate broad-spectrum inhibitory activity, direct translation to clinical efficacy in humans has not been established through controlled trials. More study is needed to identify the precise chemical responsible for the biological activity and advance to clinical trials; despite all promising research, there is still a lack of data, particularly from clinical investigations, that supports the adjunct use of A. nilotica.
4.2 Antidiabetic and Glucose-Lowering Activity
Acacia nilotica is used as a traditional anti-diabetic remedy in Bangladesh, Pakistan, Egypt, and Nigeria, and is mentioned in Ayurveda as well. Preclinical studies have investigated this application extensively. A study examining diabetic mice found that anti-hyperglycemic properties of A. nilotica leaf extract were supported by lowering of HbA1c (34%; P<0.001) and improved glucose utilization. Overall diabetic complications were mitigated as reflected by lowered hepatic (ALT, AST) and renal (creatinine, BUN) injury markers and normalization of dyslipidemia. Elevated systemic oxidative stress was lowered by increased catalase and peroxidase activities in liver, kidney, and skeletal muscle, resulting in a 32% decrease in serum MDA levels. The study concluded that A. nilotica has the potential to alleviate diabetes-related systemic complications by limiting oxidative stress, justifying the ethnopharmacological antidiabetic claim.
Research on Vachellia nilotica's anti-diabetic properties conducted in Pakistan revealed favourable hypoglycemic and hypolipidemic effects. The mechanistic basis for this involves the insulin-sensitizing flavonoids noted above, and pharmacological reports have indicated that A. nilotica extract has antioxidant activity and insulin sensitizing properties, which help with declining obesity rates and minimizing hyperlipidemia.
Evidence assessment: Antidiabetic evidence is largely from animal (rodent) models. A research proposal for a formal human study has been published, underscoring the acknowledged gap: outcomes were proposed to be measured through fasting blood sugar (FBS), glucose challenge test (GCT), glucose tolerance test (GTT), and oral glucose tolerance test (OGTT) in all studies and, in addition, 2-hour postprandial glucose and HbA1c in the human study. At the time of the most recent comprehensive review (up to 2024), robust randomized controlled trials in human subjects were not available.
4.3 Antioxidant Activity
Tannins, alkaloids, glycosides, flavonoids, and terpenoids were identified through preliminary phytochemical screening of Vachellia nilotica. The antioxidant capacity of the extract (IC₅₀ = 31.77 µg/mL in the DPPH assay) was substantiated by its rich polyphenolic profile, comprising 419.45 mg GAE/g of phenolics and 245.48 mg QE/g of flavonoids.
It also has a high phenolic content due to which it exerts a strong antioxidant action. A. nilotica is rich in polyphenolic and flavonoid compounds that act as strong antioxidants and are responsible for various biological activities like anti-diabetic, anti-aging, anticancer, antifungal prevention, and anti-inflammatory properties.
Evidence assessment: Antioxidant activity is well-characterized in vitro using DPPH, ABTS, and FRAP assays. In vivo animal studies also support systemic antioxidant effects. Human clinical data confirming meaningful antioxidant endpoints are absent from the published literature.
4.4 Anti-inflammatory and Analgesic Activity
Glucose and lipid-lowering, anti-inflammatory, analgesic, antipyretic, antioxidant, antihypertensive, antibacterial, antifungal, antiviral, and anthelmintic activities are among the most prominent documented pharmacological activities. Preclinical animal studies have confirmed significant anti-inflammatory activity, with the formalin-paw model demonstrating that leaf extract reduces both acute and chronic pain phases. All tannins, whether condensed or hydrolysable, present anti-inflammatory, bactericidal, and antimicrobial activity. Among the condensed tannins, those from Acacia nilotica present anti-inflammatory and antipyretic activity.
Evidence assessment: Predominantly preclinical. No controlled human trials specifically evaluating anti-inflammatory endpoints for V. nilotica preparations have been identified in the peer-reviewed literature to date.
4.5 Oral Health and Dental Applications
Various herbs such as Nimba (Azadirachta indica) and Babbula (Vachellia nilotica) have been used for gingivitis since ancient times. Laboratory and limited clinical work has built upon this traditional use. A. nilotica leaf cold extract showed significant (p = 0.001) antimicrobial activity as compared to chlorhexidine.
A clinical study cited in a 2024 systematic review found that original research conducted to evaluate V. nilotica in the treatment of plaque and gingival inflammation in patients with chronic generalized gingivitis showed that vachellia gel has a significant reduction in gingival and plaque index scores compared to placebo gel, without teeth discoloration or unwanted side effects.
An earlier investigation found its efficacy has been shown in the treatment of gonorrhoea, leucorrhoea, diarrhea, dysentery, and wounds.
Evidence assessment: A small number of clinical studies have evaluated dental applications, with results suggestive of benefit for plaque and gingivitis management. These studies are generally small and limited in methodological rigor. The overall oral health evidence base is stronger than for most other indications but still requires larger, well-controlled trials for definitive conclusions.
4.6 Wound Healing
From the research data, and despite the fact that human clinical trials and detailed methodological studies are scarce, V. nilotica has shown wide-ranging activities, though the most robust evidence is related to the treatment of microbial infections, diarrhea, wound and ulcer healing, and for topical application.
In animal studies, Swiss albino mice were given alloxan monohydrate to induce diabetes and excision wounds were created. The diabetic wounds were treated with various biomaterials including Vachellia nilotica extract (VN), and their effects were determined by evaluating the percent wound contraction, healing time, and histopathological analysis. Tannins are believed to be key mediators of this activity, as they are known to promote wound healing by promoting wound contraction, scavenging of free radicals, fibroblast formation, and angiogenesis. Acacia also has a potent thrombogenic, haemostatic, and antibacterial activity which improves wound cicatrization.
When combined with zinc oxide nanoparticles, it reduces toxicity while preserving antibacterial and healing activity.
Evidence assessment: Wound healing evidence is primarily derived from in vitro cell studies and animal models. Human clinical trial data are lacking.
4.7 Anthelmintic and Antiparasitic Activity
Spasmogenic and antiplasmodial activities have been documented for various parts of the plant. In vitro comparison studies have examined A. nilotica against helminth parasites, and the data suggest inhibitory effects attributable to the tannin and polyphenol content. This activity has been recognized across its range of traditional use, where the plant is commonly employed as an anthelmintic. Evidence in this area remains at the preclinical stage.
4.8 Hepatoprotective Activity
Animal studies have evaluated hepatoprotective claims. Acute in vivo toxicity studies with different concentrations of A. nilotica methanolic extract were carried out to determine the LD₅₀ value; no deaths or adverse effects were detected during the 24-hour observation period in mice treated with up to 3000 mg/kg body weight of A. nilotica. A separate study examined the hepatoprotective effect against acetaminophen-induced liver injury in Wistar rats, supporting a potential cytoprotective role. Evidence in this area is preclinical only.
4.9 Anticancer Activity (Preliminary)
Acetone and methanol extract of A. nilotica showed anti-cancer activity in vitro. A 2026 in vitro study found that the methanolic extract of Vachellia nilotica was analyzed for its phytochemical profile, antioxidant potential, antimicrobial efficacy, and in vitro anticancer activity against various cancer cell lines. Tannins, alkaloids, glycosides, flavonoids, and terpenoids were identified, and the antioxidant capacity (IC₅₀ = 31.77 µg/mL in the DPPH assay) was substantiated by its rich polyphenolic profile. Earlier in vitro work reported inhibitory activity against human hepatocellular carcinoma (HepG-2) cells. Traditionally, it has been used for treating various types of cancers of mouth, bone, and skin.
Evidence assessment: All anticancer evidence is in vitro (cell line). No animal tumor models or human studies have been published. This area must be classified as highly preliminary with no clinical relevance established.
5. Body Systems and Health Areas of Association
- Gastrointestinal system: Antidiarrheal, antiulcer, anti-dysentery, anthelmintic, anti-H. pylori activity.
- Oral and dental health: Antiplaque, antigingivitis, antibacterial against Streptococcus mutans and Lactobacillus acidophilus, anti-Candida.
- Metabolic/endocrine system: Blood glucose modulation, lipid-lowering (hypolipidemic), anti-obesity potential.
- Immune and inflammatory systems: Anti-inflammatory, antipyretic, antioxidant.
- Integumentary system (skin/wound): Wound healing, haemostatic, astringent for skin conditions.
- Respiratory system: Traditional use for cough, congestion, cold, and sore throat.
- Urogenital system: Traditional use for leucorrhoea, dysuria, urogenital infections.
- Hepatic system: Hepatoprotective effects in animal models.
- Reproductive system (traditional): Gum used for loss of libido; postpartum wound healing in West Africa.
6. Dosage Forms and Dosages Reported in Studies
No standardized pharmaceutical dose has been established for Vachellia nilotica by major regulatory or pharmacopeial bodies. Dosages referenced in the scientific literature are specific to individual preclinical and early clinical studies and are not universally applicable. The following are reported only as stated in source material:
- In an animal analgesic study, the highest analgesic effect from V. nilotica leaf extract was observed at a 50 mg/kg dose level.
- The aqueous extract of A. nilotica did not cause any adverse effects in single-dose administration; neither did 28-day administration of repeated doses of 125 mg/kg and 250 mg/kg body weight produce significant toxicological changes.
- The potential toxicity of Acacia nilotica was investigated in rats maintained on 2% and 8% acacia diets for 2 and 4 weeks, and the observed reduction in body weight and changes in some blood parameters were reversed one week after treatment termination.
- In dental/oral studies, extracts have been formulated as topical gels at concentrations sufficient to demonstrate significant reduction in gingival and plaque index scores in clinical gingivitis patients, though specific weight/volume concentrations were not uniformly reported across the source literature reviewed.
- In vitro oral antimicrobial studies have tested extracts at concentrations including 100% solution and serial dilutions, using minimum inhibitory concentration (MIC) assay by microdilution.
Acacia nilotica is available in the form of bark, pods, leaves, seeds, and gum, which can be prepared as decoctions, powders, pastes, exudates, or smoke — with preparation methods varying widely by tradition and intended application.
7. Safety Considerations
7.1 General Toxicity Profile
V. nilotica has a wide range of uses, with low toxicity, reported in different countries. Acacia nilotica is a valuable plant with medicinal properties that increasingly incites the curiosity of many researchers. Its pharmacological properties are reported in many studies, but the fact remains that the plant can be just as toxic as any modern pharmaceutical drug. Systematic review of the toxicology literature underscores that safety depends heavily on dose, duration, part used, and preparation method.
The potential toxicity was investigated in rats maintained on 2% and 8% acacia diets for 2 and 4 weeks. A significant reduction in body weight in all acacia-fed groups, and a significant decrease in hemoglobin, serum total protein, and total cholesterol in animals fed 8% acacia diet for up to 4 weeks were observed. These effects were reversed one week after treatment termination. No significant changes in serum parameters of hepatic and renal functions, fasting glucose, or triglycerides were observed. No deaths or significant histopathological changes in liver sections were noted. It was concluded that A. nilotica, at 2% and 8% levels, has a low toxicity potential.
Acute in vivo toxicity studies were carried out to determine the LD₅₀ value; no deaths or adverse effects were detected during the 24-hour observation period in mice treated with up to 3000 mg/kg body weight.
7.2 Dose-Dependent Hepatic Concerns
A 28-day repeated-dose study in animals found a differential safety profile at higher doses: 28-day administration of repeated doses of 125 and 250 mg/kg body weight of aqueous extract did not produce significant toxicological changes, except for reduced activity in lactate dehydrogenase (LDH) at 250 mg/kg. However, intake of the higher dose of 500 mg/kg body weight may have a hepatotoxic effect, based on a significant increase in AST, ALT, and ALP activity. Therefore, these enzymes should be monitored in cases using the extract for 28 days or more.
7.3 Dose and Duration Dependence
It is apparent that toxicity of Acacia nilotica fruits comes from over-dosage and longer than required duration of use or regular consumption, and from the solvent used as well. Some medicinal plants may be safe at therapeutic doses, but those that are yet to be verified scientifically should be used with caution because they may cause adverse reactions when taken above recommended doses or when taken repeatedly over a period of time.
7.4 Allergy and Sensitization
Acacia pollen is a recognized inhalant allergen. Published studies have documented allergic sensitization to regional inhalants, including acacia, among atopic patients (Al Mustafa & Dafallah, 2000; Baratawidjaja et al., 1999, as cited in the pharmacological literature). Individuals with known legume or tree pollen allergies should exercise caution.
7.5 Gastrointestinal Effects
The gum can cause minor adverse effects, including gas, bloating, nausea, and loose stools. These effects are most commonly reported with the polysaccharide gum fraction at higher doses, consistent with the fermentable fiber content.
7.6 Gaps in Human Safety Data
From the research data, and despite the fact that human clinical trials and detailed methodological studies are scarce, V. nilotica has shown wide-ranging activities, though more pharmacological and toxicological studies are required to further elucidate the mechanisms of action and potential side effects. The predominance of preclinical data means that definitive safety conclusions in humans, including drug-drug interaction profiles, cannot be drawn from existing evidence. Several preclinical and clinical studies support the potential functional and nutraceutical use of A. nilotica, owing to its diversified phytochemistry and bioactivities.
References
- Othman et al. (2024). "The Acacia (Vachellia nilotica (L.) P.J.H. Hurter & Mabb.): Traditional Uses and Recent Advances on Its Pharmacological Attributes and Potential Activities." Nutrients, 16(24), 4278. PMC11678605.
- Wikipedia: Vachellia nilotica
- Saha et al. (2018). "Acacia nilotica leaf improves insulin resistance and hyperglycemia associated acute hepatic injury and nephrotoxicity by improving systemic antioxidant status in diabetic mice." Journal of Ethnopharmacology, 210:275–286. PMID 28859934.
- Niyodusenga et al. (2017). "Hypoglycemic effects of Acacia nilotica in type II diabetes: a research proposal." PMC5530526.
- Toxicological studies of aqueous extract of Acacia nilotica root. PMC4961926.
- Protective Effect of Acacia nilotica (L.) against Acetaminophen-Induced Hepatocellular Damage in Wistar Rats. PMC3707210.
- Pharmacological Evaluation of Acacia nilotica Flower Extract against Helicobacter pylori and Human Hepatocellular Carcinoma In Vitro and In Silico. PMC10143343.
- Hypoglycemic, anti-inflammatory, and neuroprotective potentials of crude methanolic extract from Acacia nilotica L. – results of an in vitro study. PMC11077208.
- Manzo et al. (2019). "Toxicity studies of Acacia nilotica (L.): A review of the published scientific literature." J Herbmed Pharmacol, 8(3):163–172.
- Al Mustafa & Dafallah (2000). "A study on the toxicology of Acacia nilotica." Am J Chin Med, 28(1):123–129. PMID 10794124.
- Metabolomic Profiling of Antioxidant Compounds in Five Vachellia Species. PMC8539452.
- Frontiers in Nutrition (2026). Selective Anticancer Activity of Vachellia nilotica Fruit Extract: Integrated Phytochemistry with Antioxidant, Antimicrobial, and Cancer Cell Targeting.
- Review of ethnopharmacology, phytochemistry, pharmacology, and toxicity of Vachellia (Acacia) species in eastern and southern Africa. ScienceDirect.
- Vachellia nilotica – ScienceDirect Topics Overview.
- Preliminary phytochemical and elemental analysis of aqueous and fractionated pod extracts of Acacia nilotica (Thorn mimosa). PMC4279630.
- Phytochemical Wealth of Vachellia nilotica. Journal of Xi'an Shiyou University, Natural Science Edition. 2024.
- Insight on Acacia nilotica (L.) Tree through Pharaohs History as a Valuable Medicinal and Holy Plant Species in Egyptian Ecosystem. MedWin Publishers.
- Biochemistry, Medicinal Properties & Toxicity of Acacia Nilotica Fruits. Auctores Online.
- Babul – Shri Dhanwantry Ayurvedic College & Hospital. Dravyaguna Vigyan Blog.
- Wikipedia: Gum arabic
Volver